Nicotinamide adenine dinucleotide, a coenzyme critical for cellular energy metabolism that declines with age. NAD+ precursors like NMN and NR are studied as longevity interventions.

Mechanistic target of rapamycin, a key nutrient-sensing pathway that regulates cell growth and aging. Inhibiting mTOR (e.g., with rapamycin) has shown lifespan extension in multiple organisms.

A class of drugs that selectively eliminate senescent (aged, dysfunctional) cells to reduce inflammation and improve tissue function.

What is Epigenetic clock?

A biomarker based on DNA methylation patterns that estimates biological age, often more predictive of health outcomes than chronological age.

The period of life spent in good health, free from chronic diseases and disability associated with aging.

An immunosuppressant drug that inhibits the mTOR pathway. Research shows rapamycin may extend lifespan and improve age-related health outcomes in multiple species.

What is Biological age?

A measure of how well or poorly your body is functioning relative to your chronological age, assessed through biomarkers such as DNA methylation, telomere length, and blood panels.

What is Caloric restriction?

A dietary regimen that reduces calorie intake without malnutrition. Caloric restriction is one of the most studied interventions shown to extend lifespan across species.

Protective caps at the ends of chromosomes that shorten with each cell division. Telomere length is associated with aging and age-related diseases.

A state in which cells permanently stop dividing but resist death, accumulating with age and secreting inflammatory factors that damage surrounding tissue.

A second-generation epigenetic clock that predicts time to death and is considered one of the most accurate measures of biological aging.

What is Inflammaging?

Chronic, low-grade inflammation that increases with age and contributes to the development of age-related diseases including cardiovascular disease, diabetes, and neurodegeneration.

The large-scale study of proteins in biological systems. In longevity research, proteomics identifies blood protein signatures that predict biological age and disease risk.

What is Yamanaka factors?

A set of four transcription factors (Oct4, Sox2, Klf4, c-Myc) that can reprogram adult cells to a pluripotent state. Partial reprogramming with Yamanaka factors is being explored to reverse cellular aging.

Nicotinamide mononucleotide, a precursor to NAD+ that is widely studied as a supplement to boost cellular energy and combat age-related decline.

A gene-editing technology that allows precise modifications to DNA. In longevity research, CRISPR is used to study and potentially modify genes associated with aging.

Umoja Biopharma Announces Unveiling of UB-VV500 in Upcoming Poster Presentation at the American Society of Gene & Cell Therapy Annual Meeting

Umoja Biopharma has announced the acceptance of a poster presentation for its innovative dual-targeted BCMA x GPRC5D in vivo CAR T cell therapy, UB-VV500, aimed at treating multiple myeloma. This development marks a significant shift in the therapeutic landscape for multiple myeloma, moving away from single-targeted therapies to combination strategies that address the challenges of antigen escape and disease heterogeneity. The preclinical data will be showcased at the upcoming ASGCT Annual Meeting, highlighting the potential of UB-VV500 to enhance treatment efficacy as patients progress through existing BCMA-directed therapies.

The significance of UB-VV500 lies in its design, which leverages the VivoVec™ in vivo gene delivery technology to harness the patient’s immune system more effectively. Andrew Scharenberg, M.D., emphasizes that the future of multiple myeloma treatment will increasingly rely on combination products that are engineered to provide greater and more durable efficacy. The expectation is that UB-VV500 will not only improve patient outcomes but also set a new standard for how combination therapies are approached in this space.

The concrete implication of this advancement is the anticipated initiation of a Phase 1 clinical trial for UB-VV500 by the end of 2026, which could significantly accelerate the timeline for developing effective therapies in multiple myeloma. As the field shifts towards dual-targeting strategies, this therapy could redefine treatment paradigms and influence future research directions in immunotherapy for hematological cancers. The upcoming presentation at ASGCT will provide critical insights into the preclinical findings, potentially guiding subsequent clinical applications and research initiatives.

Source: globenewswire.com